Summary

Focusing on the transformative impact of artificial intelligence, this award recognises the most innovative AI applications solving critical challenges in cell culture, bioprocessing, and advanced therapies.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Application of artificial intelligence to solve critical challenges in cell culture, bioprocessing or advanced therapies field.
• Use of AI to enhance processes such as cell line development, bioprocessing, manufacturing etc.
• Open to pharma & biotech companies only.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Celebrating groundbreaking advancements in cell therapy development, this award recognises innovations with a clear pathway to regulatory approval and commercialisation. It honours the pioneering developments shaping the future of cell-based treatments and their potential to transform patient care.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Significant progress in the development of a novel cell therapy, this can use a gene therapy approach too.
• Advancements in any R&D stage that highlight innovation or address unmet medical needs.
• A clear and promising pathway toward regulatory approval or commercialisation.

Entries should be based on activities undertaken between 1 January 2024 and 30 June 2025.

Summary

This award highlights exceptional achievements in gene therapy design and development, recognising innovations with a strong strategy for regulatory approval or market entry.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Exceptional innovation in the design, implementation of a gene therapy programme or significant progress in the development of a novel gene therapy.
• Advancements in any R&D stage that highlights innovation or addresses unmet medical needs.
• A well-defined strategy for regulatory approval or market entry or commercialisation.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This Award highlights transformative advancements in upstream and downstream processes, innovations and technologies. Recognising innovations that enhance scalability, efficiency, and product quality in CGT production, it celebrates breakthroughs driving the future of biomanufacturing.

Who Should Enter

This Award is open to any company [other than vendors] that can demonstrate the following:

• Development, implementation, or successful application of innovative upstream / downstream bioprocessing technologies that significantly advance the field.
• Improvements in scalability, operational efficiency, and product quality, enhancing bioprocessing for cell and gene therapy (CGT) production.
• Evidence of a measurable impact on CGT production processes, with clear outcomes that contribute to advancing the field or improving therapeutic production.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This Award honours outstanding contributions to cell biology and leadership in advancing cell-based technologies. Recognising sustained growth and industry impact, it celebrates biotech companies driving progress in research, development, and commercialisation.

Who Should Enter

This Award is open to any biotech company that can demonstrate the following:

• Outstanding contributions to the field of cell biology, with innovative research, technologies, or therapies that have advanced the understanding of cellular processes.
• Proven ability to drive significant progress in cell-based technologies, therapies, or platforms, influencing the wider biomedical or pharmaceutical industry.
• Leadership in the field of cell biology with sustained growth, including expanding capabilities, strategic collaborations, and fostering innovation within the company.
• Qualifying size: must employ fewer than 500 people.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Recognising exceptional leadership in biotech, this award celebrates CEOs who drive innovation, accelerate growth, and build high-performing teams within companies of up to 500 employees. It honours visionary leaders shaping the future of medicine and patient care.

Who Should Enter

This Award is open to any biotech company CEO that can demonstrate the following:

• Exceptional leadership, guiding the company through key milestones in biotech innovation, development, and commercialisation.
• Evidence of significant growth in company revenue, market share, or product pipeline under the CEO’s leadership, including successful funding rounds, acquisitions, or partnerships.
• Ability to build high-performing teams, foster collaboration, and create a workplace culture that encourages talent retention, diversity, and creativity.
• Company size: max 500 employees.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Recognising excellence in supporting the discovery, development, and manufacturing of cell and gene therapies, this award celebrates CDMOs with a track record of innovation, quality outcomes, and reliable on-time delivery in advanced therapy manufacturing.

Who Should Enter

This Award is open to CDMOs that can demonstrate the following:

• Proven expertise in supporting the discovery, development or manufacturing of cell and gene therapies.
• Successful execution of projects with a track record of on-time delivery and quality outcomes.
• Evidence of innovation in manufacturing processes, such as scalability, cost-effectiveness, or sustainability.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Celebrating the power of partnership, this award recognises groundbreaking achievements through collaboration between pharma, biotech, and academia. It highlights innovative joint efforts that have advanced research, development, or regulatory progress in the field.

Who Should Enter

This Award is open to any collaboration (of 2 or more companies) that can demonstrate the following:

• Evidence of significant milestones or breakthroughs achieved through collaboration that have directly advanced the field of cell and gene therapies (e.g., regulatory approvals, clinical advancements, novel therapies).
• A partnership that demonstrates innovative approaches to collaboration, whether in research, development, or regulatory processes. This could include novel strategies, shared technologies, or unique synergistic contributions from all parties involved.
• The partnership must be between pharma - biotech - academia.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This award recognises leadership in fostering diversity, inclusion, and mentorship within the industry. It honours those driving meaningful change, creating pathways for underrepresented groups, and empowering the next generation of scientists and leaders.

Who Should Enter

This Award is open to any individual that can demonstrate the following:

• Demonstrated leadership and innovative contributions to the field.
• Proven ability to drive forward significant change in the industry through visionary approaches or novel technologies, focusing on the improvement of treatments or therapies.
• Demonstrated commitment to mentoring the next generation of scientists, advocating for diversity and inclusion, and creating pathways for others to succeed.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This award recognises an outstanding academic laboratory that has demonstrated excellence and innovation in cell culture processes, bioprocessing, and cell & gene therapy research. Nominees should showcase advancements that have significantly enhanced laboratory efficiency, reproducibility, or scalability in the field.

Who Should Enter

This Award is open to any laboratory who can demonstrate the following:

• Development or optimisation of advanced cell culture techniques, including 3D cultures, organoids, or automated systems.
• Implementation of novel media formulations, bioreactors, or culture conditions to enhance cell viability and yield.
• Use of AI, machine learning, digital twins, or robotics to streamline and improve cell culture processes.
• Contribution to scalable and efficient cell expansion strategies for clinical or preclinical applications.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Honouring exceptional contributions to patient education, access, and involvement in CGT development, this award recognises impactful advocacy programs with measurable outcomes. It celebrates individuals and organizations championing patient-centered progress.

Who Should Enter

This Award is open to any patient advocacy group that can demonstrate the following:

• Outstanding contributions to patient education, access, or involvement in CGT development.
• Creation of impactful patient advocacy programmes or collaborations.
• Evidence of tangible outcomes improving patient participation or awareness.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Recognising leadership in advancing cell-based technologies, this award celebrates sustained growth and innovation in a pharmaceutical setting. It honours companies making a significant impact in the development and commercialization of cutting-edge therapies.

Who Should Enter

This Award is open to any large (1,000+ employees) pharma company that can demonstrate the following: 

• Outstanding contributions to cell biology through innovative research, technologies, or therapies that have advanced the understanding of cellular processes.
• Proven ability to drive significant progress in cell-based technologies, therapies, or platforms, with a substantial impact on the broader biomedical or pharmaceutical industry.
• Leadership in the field of cell biology, with sustained growth, including the expansion of capabilities, strategic collaborations, and a commitment to fostering innovation within the company
• Qualifying company size: must employ 1,000+ people.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Recognising excellence in regulatory strategy, this award celebrates the achievement of critical milestones that advance cell and gene therapy programs. It highlights innovative approaches to overcoming regulatory challenges and accelerating progress toward market approval.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Successful attainment of a critical regulatory milestone, such as IND approval, NDA submission, or similar achievements.
• Development of innovative strategies or approaches to meet or exceed regulatory requirements.
• Evidence of impact on advancing CGT programmes through regulatory success.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This award showcases the most promising early-stage companies driving scientific innovation in advanced therapies. It recognises start-ups demonstrating strong potential for impact, from breakthrough research to early clinical success.

Who Should Enter

This Award is open to any CGT start-up company that can demonstrate the following:

• A strong scientific foundation and innovative approach to addressing challenges in gene or cell therapy.
• Notable achievements in early-stage development or securing strategic partnerships.
• Clear potential for significant impact within the advanced therapies field.
• Up to 30 employees and operating no more than 5 years.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

This award highlights cutting-edge strategies optimising the supply chain for cell and gene therapies. Recognising innovations in scalability, cost-efficiency, quality control, and logistics, it celebrates advancements ensuring seamless delivery of life-saving treatments.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Development or implementation of innovative strategies, technologies, or processes that optimise the supply chain for cell & gene therapies.
• Novel approaches to overcome challenges such as scalability, cost-efficiency, quality control, and logistics.
• Significant efforts to streamline the entire supply chain process.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Honouring initiatives that promote sustainable growth and accessibility in cell and gene therapy, this award recognises scientific innovation, strategic partnerships, and long-term impact. It celebrates efforts that drive environmental responsibility and equitable patient access.

Who Should Enter

This Award is open to any pharma or biotech company that can demonstrate the following:

• Scientific innovation: addressing key challenges in cell and gene therapy with innovative solutions in processing, manufacturing, or scalability.
• Strategic partnerships: achievements in developing or securing strategic partnerships to support sustainable growth and impact in the field.
• Long-term impact: clear potential for significant, lasting change, improving accessibility, cost-effectiveness, or patient outcomes in cell and gene therapy.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.

Summary

Recognising groundbreaking technology shaping the future of advanced therapies, this award honours innovations that improve development speed, manufacturing efficiency, and overall impact. It celebrates disruptive solutions driving transformation across the industry.

Who Should Enter

This Award is open to any vendor or platform provider that can demonstrate the following:

• Development or application of ground-breaking technology that significantly advances the field of advanced therapies.
• Evidence of measurable improvements in areas such as: speed of development, cost-efficiency in manufacturing, bioprocessing, or other.
• Technologies that hold the promise to transform the future of advanced therapies, creating pathways for new treatments, platforms, or processes.

Entries should be based on activities undertaken between 1 Jan 2024 – 30 June 2025.